TY  - JOUR 
AU  - Taborda Gómez, Claudia
AU  - Fernández, Florencia
AU  - Jara, Agustín
AU  - Borda, Natalia
AU  - Moscovicz, Franco
AU  - Yauri-Huaman, Yessenia
AU  - Cáceres Robles, Rodrigo
AU  - Pacheco Otalora, Luis
AU  - Lazarowski, Alberto
AU  - Auzmendi, Jerónimo
PY  - 2026
UR  - http://hdl.handle.net/10366/172757
AB  - [EN] Introduction. In recent years, cannabidiol (CBD) has been used as an adjunct therapy to anti-seizure medications for the control of seizures in patients with drug-resistant epilepsy. In addition to its anticonvulsant effect, CBD also has...
LA  - eng
PB  - MDPI
KW  - Cannabidiol
KW  - Seizure threshold
KW  - Status epilepticus
KW  - Epileptogenesis
KW  - Epilepsy
KW  - Pentylenetetrazole
KW  - Status Epilepticus
KW  - Cannabidiol
TI  - Subchronic Cannabidiol (CBD) Treatment During the Silent Period Fails to Prevent Increased Seizure Susceptibility Following Lithium-Pilocarpine-Induced Status Epilepticus
DO  - 10.3390/brainsci16080851
T2  - Brain Sciences
VL  - 16
M2  - 851
ER  -